|
[1]
|
Ong, K.L., Stafford, L.K., McLaughlin, S.A., et al. (2023) Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 402, 203-234.
|
|
[2]
|
Saran, R., Robinson, B., Abbott, K.C., et al. (2018) US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 71, A7.
|
|
[3]
|
Ling, J., Ng, J.K.C., Chan, J.C.N. and Chow, E. (2022) Use of Continuous Glucose Monitoring in the Assessment and Management of Patients with Diabetes and Chronic Kidney Disease. Frontiers in Endocrinology, 13, Article 869899. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Rhee, C.M., Kovesdy, C.P., You, A.S., Sim, J.J., Soohoo, M., Streja, E., et al. (2018) Hypoglycemia-Related Hospitalizations and Mortality among Patients with Diabetes Transitioning to Dialysis. American Journal of Kidney Diseases, 72, 701-710. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Abe, M. and Kalantar-Zadeh, K. (2015) Haemodialysis-Induced Hypoglycaemia and Glycaemic Disarrays. Nature Reviews Nephrology, 11, 302-313. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Gianchandani, R.Y., Neupane, S., Iyengar, J.J. and Heung, M. (2017) Pathophysiology and Management of Hypoglycemiain End-Stage Renal Disease Patients: A Review. Endocrine Practice, 23, 353-362. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Gosmanov, A.R., Gosmanova, E.O. and Kovesdy, C.P. (2015) Evaluation and Management of Diabetic and Non-Diabetic Hypoglycemia in End-Stage Renal Disease. Nephrology Dialysis Transplantation, 31, 8-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Rahhal, M., Gharaibeh, N.E., Rahimi, L. and Ismail-Beigi, F. (2019) Disturbances in Insulin-Glucose Metabolism in Patients with Advanced Renal Disease with and without Diabetes. The Journal of Clinical Endocrinology & Metabolism, 104, 4949-4966. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Galindo, R.J., Beck, R.W., Scioscia, M.F., Umpierrez, G.E. and Tuttle, K.R. (2020) Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocrine Reviews, 41, 756-774. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Klein, K.R., Pate, V., Assimon, M.M., Stürmer, T., Buse, J.B. and Flythe, J.E. (2022) Antihyperglycemic Medication Use among U.S. Adults with Hemodialysis-Dependent Kidney Disease and Comorbid Diabetes. Diabetes Care, 45, 126-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Chen, T.K., Knicely, D.H. and Grams, M.E. (2019) Chronic Kidney Disease Diagnosis and Management. Journal of the American Medical Association, 322, 1294-1304. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
蹇丽君, 张凌, 关明镜, 等. 含糖透析液对合并糖尿病的维持性血液透析患者血糖、血压和心率变异性的影响[J]. 西部医学, 2024, 36(5): 776-780.
|
|
[13]
|
Kazempour-Ardebili, S., Lecamwasam, V.L., Dassanyake, T., Frankel, A.H., Tam, F.W.K., Dornhorst, A., et al. (2009) Assessing Glycemic Control in Maintenance Hemodialysis Patients with Type 2 Diabetes. Diabetes Care, 32, 1137-1142. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Jin, Y., Su, X., Yin, G., Xu, X., Lou, J., Chen, J., et al. (2015) Blood Glucose Fluctuations in Hemodialysis Patients with End Stage Diabetic Nephropathy. Journal of Diabetes and its Complications, 29, 395-399. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sobngwi, E., Ashuntantang, G., Ndounia, E., Dehayem, M., Azabji-Kenfack, M., Kaze, F., et al. (2010) Continuous Interstitial Glucose Monitoring in Non-Diabetic Subjects with End-Stage Renal Disease Undergoing Maintenance Haemodialysis. Diabetes Research and Clinical Practice, 90, 22-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Penckofer, S., Quinn, L., Byrn, M., Ferrans, C., Miller, M. and Strange, P. (2012) Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technology & Therapeutics, 14, 303-310. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Selvin, E., Rawlings, A.M., Grams, M., Klein, R., Steffes, M. and Coresh, J. (2014) Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions. Clinical Chemistry, 60, 1409-1418. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Hirsch, I.B. (2015) Glycemic Variability and Diabetes Complications: Does It Matter? of Course It Does! Diabetes Care, 38, 1610-1614. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Ravi, R., Balasubramaniam, V., Kuppusamy, G. and Ponnusankar, S. (2021) Current Concepts and Clinical Importance of Glycemic Variability. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 627-636. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Mo, Y., Lu, J. and Zhou, J. (2023) Glycemic Variability: Measurement, Target, Impact on Complications of Diabetes and Does It Really Matter? Journal of Diabetes Investigation, 15, 5-14. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Kalantar-Zadeh, K., Kopple, J.D., Regidor, D.L., Jing, J., Shinaberger, C.S., Aronovitz, J., et al. (2007) A1C and Survival in Maintenance Hemodialysis Patients. Diabetes Care, 30, 1049-1055. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Rossing, P., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., Khunti, K., et al. (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Sinclair, A.J., Dashora, U., George, S. and Dhatariya, K. (2020) Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Clinical Guideline Inpatient Care of the Frail Older Adult with Diabetes: An Executive Summary. Diabetic Medicine, 37, 1981-1991. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Alalawi, F. and Bashier, A. (2021) Management of Diabetes Mellitus in Dialysis Patients: Obstacles and Challenges. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 1025-1036. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hoshino, J., Larkina, M., Karaboyas, A., Bieber, B.A., Ubara, Y., Takaichi, K., et al. (2017) Unique Hemoglobin A1c Level Distribution and Its Relationship with Mortality in Diabetic Hemodialysis Patients. Kidney International, 92, 497-503. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hill, C.J., Maxwell, A.P., Cardwell, C.R., Freedman, B.I., Tonelli, M., Emoto, M., et al. (2014) Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated with Hemodialysis: A Meta-Analysis. American Journal of Kidney Diseases, 63, 84-94. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Adler, A., Casula, A., Steenkamp, R., Fogarty, D., Wilkie, M., Tomlinson, L., et al. (2014) Association between Glycemia and Mortality in Diabetic Individuals on Renal Replacement Therapy in the U.K. Diabetes Care, 37, 1304-1311. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Coelho, S. (2015) What Is the Role of Hba1c in Diabetic Hemodialysis Patients? Seminars in Dialysis, 29, 19-23. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Battelino, T., Alexander, C.M., Amiel, S.A., Arreaza-Rubin, G., Beck, R.W., Bergenstal, R.M., et al. (2023) Continuous Glucose Monitoring and Metrics for Clinical Trials: An International Consensus Statement. The Lancet Diabetes & Endocrinology, 11, 42-57. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Vaddiraju, S., Burgess, D.J., Tomazos, I., Jain, F.C. and Papadimitrakopoulos, F. (2010) Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises. Journal of Diabetes Science and Technology, 4, 1540-1562. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Facchinetti, A. (2016) Continuous Glucose Monitoring Sensors: Past, Present and Future Algorithmic Challenges. Sensors, 16, Article 2093. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Shilo, S., Keshet, A., Rossman, H., Godneva, A., Talmor-Barkan, Y., Aviv, Y., et al. (2024) Continuous Glucose Monitoring and Intrapersonal Variability in Fasting Glucose. Nature Medicine, 30, 1424-1431. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Navaneethan, S.D., Zoungas, S., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., et al. (2023) Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine, 176, 381-387. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Battelino, T., Danne, T., Bergenstal, R.M., Amiel, S.A., Beck, R., Biester, T., et al. (2019) Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, 42, 1593-1603. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Chen, X., Duan, Y. and Zhou, Y. (2020) Effects of Hemodialysis and Peritoneal Dialysis on Glycometabolism in Patients with End-Stage Diabetic Nephropathy. Blood Purification, 50, 506-512. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Zinman, B., Marso, S.P., Poulter, N.R., Emerson, S.S., Pieber, T.R., Pratley, R.E., et al. (2017) Day-to-Day Fasting Glycaemic Variability in DEVOTE: Associations with Severe Hypoglycaemia and Cardiovascular Outcomes (DEVOTE 2). Diabetologia, 61, 48-57. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Pieber, T.R., Marso, S.P., McGuire, D.K., Zinman, B., Poulter, N.R., Emerson, S.S., et al. (2017) DEVOTE 3: Temporal Relationships between Severe Hypoglycaemia, Cardiovascular Outcomes and Mortality. Diabetologia, 61, 58-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Singhsakul, A., Supasyndh, O. and Satirapoj, B. (2019) Effectiveness of Dose Adjustment of Insulin in Type 2 Diabetes among Hemodialysis Patients with End-Stage Renal Disease: A Randomized Crossover Study. Journal of Diabetes Research, 2019, 1-5. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Tumlinson, R., Blaine, E., Colvin, M., Haynes, T.G. and Whitley, H.P. (2021) 397-P: Insulin Dosing Adjustments in Patients with Diabetes on Peritoneal Dialysis or Hemodialysis: A Systematic Review of the Literature. Diabetes, 70, 397. [Google Scholar] [CrossRef]
|
|
[40]
|
Ebert, T., Sattar, N., Greig, M., Lamina, C., Froissart, M., Eckardt, K., et al. (2024) Use of Analog and Human Insulin in a European Hemodialysis Cohort with Type 2 Diabetes: Associations with Mortality, Hospitalization, MACE, and Hypoglycemia. American Journal of Kidney Diseases, 83, 18-27. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Zoungas, S., de Galan, B.E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., et al. (2009) Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients with Type 2 Diabetes. Diabetes Care, 32, 2068-2074. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Wong, M.G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M.E., et al. (2016) Long-Term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: Advance-On. Diabetes Care, 39, 694-700. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Flynn, C. and Bakris, G.L. (2013) Noninsulin Glucose-Lowering Agents for the Treatment of Patients on Dialysis. Nature Reviews Nephrology, 9, 147-153. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Papaetis, G. (2022) Pioglitazone in Diabetic Kidney Disease: Forgotten but Not Gone. Archives of Medical Science—Atherosclerotic Diseases, 7, 78-93. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Padhi, S., Nayak, A.K. and Behera, A. (2020) Type II Diabetes Mellitus: A Review on Recent Drug Based Therapeutics. Biomedicine & Pharmacotherapy, 131, Article 110708. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Su, J., Luo, Y., Hu, S., Tang, L. and Ouyang, S. (2023) Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents. International Journal of Molecular Sciences, 24, Article 13381. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Zanchi, A., Tappy, L., Lê, K., Bortolotti, M., Theumann, N., Halabi, G., et al. (2014) Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study. PLOS ONE, 9, e109134. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Cheng, H.S., Tan, W.R., Low, Z.S., Marvalim, C., Lee, J.Y.H. and Tan, N.S. (2019) Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. International Journal of Molecular Sciences, 20, Article 5055. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Heerspink, H.J.L., Berger, S. and Gansevoort, R.T. (2023) Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation. Clinical Journal of the American Society of Nephrology, 18, 1500-1502. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Yen, F., Hwu, C., Liu, J., Wu, Y., Chong, K. and Hsu, C. (2024) Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients with Stage 5 Chronic Kidney Disease. Annals of Internal Medicine, 177, 693-700. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Solomon, J., Festa, M.C., Chatzizisis, Y.S., Samanta, R., Suri, R.S. and Mavrakanas, T.A. (2023) Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Kidney Disease. Pharmacology & Therapeutics, 242, Article 108330. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Nauck, M.A. and Müller, T.D. (2023) Incretin Hormones and Type 2 Diabetes. Diabetologia, 66, 1780-1795. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
de Boer, I.H., Khunti, K., Sadusky, T., Tuttle, K.R., Neumiller, J.J., Rhee, C.M., et al. (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (Kdigo). Kidney International, 102, 974-989. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Granhall, C., Søndergaard, F.L., Thomsen, M. and Anderson, T.W. (2018) Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clinical Pharmacokinetics, 57, 1571-1580. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Sourris, K.C., Ding, Y., Maxwell, S.S., Al-Sharea, A., Kantharidis, P., Mohan, M., et al. (2024) Glucagon-Like Peptide-1 Receptor Signaling Modifies the Extent of Diabetic Kidney Disease through Dampening the Receptor for Advanced Glycation End Products-Induced Inflammation. Kidney International, 105, 132-149. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Rossing, P., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., Khunti, K., et al. (2022) Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on Rapidly Emerging New Evidence. Kidney International, 102, 990-999. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Caruso, I. and Giorgino, F. (2024) Renal Effects of GLP-1 Receptor Agonists and Tirzepatide in Individuals with Type 2 Diabetes: Seeds of a Promising Future. Endocrine, 84, 822-835. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Sarnak, M.J., Auguste, B.L., Brown, E., Chang, A.R., Chertow, G.M., Hannan, M., et al. (2022) Cardiovascular Effects of Home Dialysis Therapies: A Scientific Statement from the American Heart Association. Circulation, 146, e146-e164. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Brown, E., Heerspink, H.J.L., Cuthbertson, D.J. and Wilding, J.P.H. (2021) SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications. The Lancet, 398, 262-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Palmer, S.C., Tendal, B., Mustafa, R.A., et al. (2021) Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. British Medical Journal, 372, m4573.
|
|
[61]
|
Rosenstock, J., Wysham, C., Frías, J.P., Kaneko, S., Lee, C.J., Fernández Landó, L., et al. (2021) Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomized, Phase 3 Trial. The Lancet, 398, 143-155. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Ludvik, B., Giorgino, F., Jódar, E., Frias, J.P., Fernández Landó, L., Brown, K., et al. (2021) Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-On to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomized, Open-Label, Parallel-Group, Phase 3 Trial. The Lancet, 398, 583-598. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Urva, S., Quinlan, T., Landry, J., Martin, J. and Loghin, C. (2021) Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics, 60, 1049-1059. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Sinha, R., Papamargaritis, D., Sargeant, J.A. and Davies, M.J. (2023) Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity & Metabolic Syndrome, 32, 25-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., et al. (2018) Dorzagliatin Monotherapy in Chinese Patients with Type 2 Diabetes: A Dose-Ranging, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. The Lancet Diabetes & Endocrinology, 6, 627-636. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Toulis, K.A., Nirantharakumar, K., Pourzitaki, C., Barnett, A.H. and Tahrani, A.A. (2020) Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. Drugs, 80, 467-475. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Zhu, D., Li, X., Ma, J., Zeng, J., Gan, S., Dong, X., et al. (2022) Dorzagliatin in Drug-Naïve Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. Nature Medicine, 28, 965-973. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Miao, J., Fu, P., Ren, S., Hu, C., Wang, Y., Jiao, C., et al. (2021) Effect of Renal Impairment on the Pharmacokinetics and Safety of Dorzagliatin, a Novel Dual-Acting Glucokinase Activator. Clinical and Translational Science, 15, 548-557. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Chen, L., Zhang, J., Sun, Y., Zhao, Y., Liu, X., Fang, Z., et al. (2023) A Phase I Open-Label Clinical Trial to Study Drug-Drug Interactions of Dorzagliatin and Sitagliptin in Patients with Type 2 Diabetes and Obesity. Nature Communications, 14, Article No. 1405. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Konkwo, C. and Perry, R.J. (2020) Imeglimin: Current Development and Future Potential in Type 2 Diabetes. Drugs, 81, 185-190. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., et al. (2018) Inflammageing and Metaflammation: The Yin and Yang of Type 2 Diabetes. Ageing Research Reviews, 41, 1-17. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Galindo, R.J., Inselman, S.A., Umpierrez, G.E., Moazzami, B., Munoz Mendoza, J., Ali, M.K., et al. (2023) National Trends in Glucagon Prescriptions among U.S. Adults with Diabetes and End-Stage Kidney Disease Treated by Dialysis: 2013-2017. Diabetes Care, 46, e130-e132. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Carrero, J.J., González-Ortiz, A., Avesani, C.M., Bakker, S.J.L., Bellizzi, V., Chauveau, P., et al. (2020) Plant-Based Diets to Manage the Risks and Complications of Chronic Kidney Disease. Nature Reviews Nephrology, 16, 525-542. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Wang, A.Y., Sea, M.M., Ng, K., Wang, M., Chan, I.H., Lam, C.W., et al. (2019) Dietary Fiber Intake, Myocardial Injury, and Major Adverse Cardiovascular Events among End-Stage Kidney Disease Patients: A Prospective Cohort Study. Kidney International Reports, 4, 814-823. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Sacks, D.B., Arnold, M., Bakris, G.L., Bruns, D.E., Horvath, A.R., Lernmark, Å., et al. (2023) Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care, 46, e151-e199. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Kojima, M., Hayano, J., Suzuki, S., Seno, H., Kasuga, H., Takahashi, H., et al. (2010) Depression, Alexithymia and Long-Term Mortality in Chronic Hemodialysis Patients. Psychotherapy and Psychosomatics, 79, 303-311. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Basiri, R., Seidu, B. and Cheskin, L.J. (2023) Key Nutrients for Optimal Blood Glucose Control and Mental Health in Individuals with Diabetes: A Review of the Evidence. Nutrients, 15, Article 3929. [Google Scholar] [CrossRef] [PubMed]
|